Priyanka Solanky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Priyanka Solanky has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Brigette Kobs
Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School
1 shared publication - Christine Guo Lian
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - David R. Liu
Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
1 shared publication - Eliezer Mendel Van Allen
Broad Institute of MIT and Harvard, Cambridge, USA
1 shared publication - Elizabeth Iannotti Buchbinder
Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA
1 shared publication - Patrick Alexander Ott
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
1 shared publication
Latest Publications
- Open Access
Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.
Open AccessImmunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.